相关临床试验
665
122 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1826
进行中（未招募）
66
9.9%
已完成
252
37.9%
Enrolling By Invitation
2
0.3%
尚未招募
54
8.1%
招募中
113
17.0%
暂停
4
0.6%
终止
20
3.0%
Unknown
140
21.1%
撤回
14
2.1%
暂无批准数据
- DNA sequencing of normal esophageal tissue from cancer patients shows chemotherapy and radiotherapy alter which mutant cell clones expand in healthy tissue. - Patients who received chemoradiotherapy (CROSS) had double the proportion of tissue carrying TP53 and PPM1D mutations compared with other treatment groups. - Combination chemotherapy increased normal cells carrying mutations linked to resistance to 5-fluorouracil, potentially protecting healthy tissue from toxicity. - Researchers found no chemotherapy-specific mutational signatures, suggesting most detected mutant clones pre-existed therapy and were selected rather than newly generated.
- A one-year-old boy with severe sagittal craniosynostosis became the first patient worldwide to receive custom-designed "super elastic" nitinol springs to gradually reshape his skull. - The new springs, developed by Great Ormond Street Hospital and UCL, offer greater flexibility than traditional stainless-steel springs and may prevent the need for further surgery. - Experts say the technology allows children to avoid longer, more invasive operations and should reduce blood transfusion rates. - Nine weeks after the 45-minute procedure, the springs were removed once the skull reached the desired outcome, with the child reported to be hitting normal milestones.
- A 70-year British cohort study found that persistent financial hardship across working-age adulthood is associated with poorer processing speed and verbal memory by age 53. - Sustained—not intermittent—financial adversity mattered most, supporting the accumulation model of life-course disadvantage on cognitive health. - Brain imaging in early 70s showed larger ventricular volume in those with persistent low income; men, APOE-ε4 carriers, and those with disadvantaged childhoods were most vulnerable to accelerated brain atrophy. - Researchers suggest that preventing chronic financial strain may support cognitive health, though the observational study does not establish causality.
- The STIMULATE-ICP phase 3 cluster-randomized trial enrolled 1,152 Long COVID patients across 114 NHS primary care networks, finding a 12.6% reduction in fatigue scores with specialist integrated care. - Multi-organ MRI (Coverscan) offered no incremental improvement in fatigue or quality of life at 12 or 24 weeks compared with usual specialist care alone. - Digital rehabilitation via the Living With COVID Recovery app showed a small, statistically significant improvement in fatigue at 24 weeks (−1.14 points on FAS, P=0.023), but the clinical significance remains uncertain. - The trial demonstrates the feasibility of pragmatic cluster-randomized designs for evaluating complex care pathways in post-infectious conditions, though unblinded interventions and heterogeneous protocols present inherent methodological limitations.
- A UCL-led single-cell transcriptomics study of the fetal-maternal interface has uncovered distinct cellular processes driving severe preeclampsia, including hypoxia, fibrosis, and dysfunctional blood vessel formation in placental cells. - Researchers found molecular signatures of immune dysfunction involving mitochondrial and interferon signaling in maternal tissues, helping explain the systemic nature of the condition. - The study compared 10 severe preeclampsia cases with 10 healthy pregnancies, using high-resolution genomic testing to analyze thousands of individual cells across placenta, myometrium, and chorioamniotic membranes. - Findings point to specific biological processes that could be targeted with treatments, particularly in early-onset cases, potentially reducing premature births and fatalities associated with the condition.
- The convergence of IoT and AI is enabling continuous patient monitoring, predictive analytics, and automated clinical decision support, transforming smart healthcare systems. - Wearable sensors and connected medical devices generate vast physiological data streams that AI can process for early detection of clinical deterioration and chronic disease management. - Significant barriers remain, including data interoperability challenges, security and privacy concerns, and the need for validated, unbiased AI models for clinical use. - This Research Topic invites contributions examining technological, clinical, and ethical dimensions of AI-driven IoT integration, from edge computing architectures to regulatory frameworks.
- Blue Earth Therapeutics and UCL have dosed the first participant in a Phase 1 trial of Actinium (²²⁵Ac) rhPSMA-10.1 Injection for metastatic castrate-resistant prostate cancer. - The UCL-sponsored study will evaluate safety, tolerability, and radiation dosimetry in patients with PSMA-positive mCRPC whose disease has progressed after prior therapy. - The alpha-emitting radiopharmaceutical delivers high-energy, short-range radiation to prostate cancer lesions, aiming for potent anti-tumour activity while limiting damage to healthy tissue. - An estimated 50,055 new cases of metastatic prostate cancer are forecast in the U.S. for 2025, with a five-year survival rate of only 40.1% for newly diagnosed patients.
- University College London and Eisai have signed a five-year extension to their drug discovery collaboration, continuing the partnership through 2030 to tackle Alzheimer's, Parkinson's, and ALS. - The alliance has already produced the anti-MTBR tau antibody E2814, now in Phase II/III trials for dominantly inherited Alzheimer's disease and Phase II for sporadic early AD. - Eight drug discovery projects have been supported through £10 million in investment to date, with further funding committed over the next five years. - The partnership has generated more than 30 scientific publications and presentations, emphasizing knowledge exchange alongside therapeutic development.
- UCL scientists are developing a first-of-its-kind gene therapy for CTLA-4 insufficiency, a rare inherited immune disorder with limited treatment options. - The approach uses CRISPR/Cas9 to replace the faulty CTLA-4 gene in patients' own T cells, addressing the root cause rather than managing symptoms. - Early pre-clinical studies show corrected cells lead to better immune regulation, with a Phase I trial in up to 8 patients planned for 2028. - The collaboration involves UCL, NHS Blood and Transplant, Great Ormond Street Hospital, and is funded by medical research organization LifeArc.
- Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product from the Galien Foundation. - The award was selected by a UK Awards Committee comprising 12 leading experts in UK healthcare. - Dr. Martin Pule, Founder and CSO of Autolus, highlighted the company's collaboration with University College London in translating pioneering research into new treatments. - The Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research, recognizing excellence in scientific innovation.
